Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Endocrine
Erschienen in: Endocrine 2/2015

01.03.2015 | Review

Prediabetes and associated disorders

verfasst von: Martin Buysschaert, José Luís Medina, Michael Bergman, Avni Shah, Jaqueline Lonier

Erschienen in: Endocrine | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Prediabetes represents an elevation of plasma glucose above the normal range but below that of clinical diabetes. Prediabetes includes individuals with IFG, IGT, IFG with IGT and elevated HbA1c levels. Insulin resistance and β-cell dysfunction are characteristic of this disorder. The diagnosis of prediabetesis is vital as both IFG and IGT are indeed well-known risk factors for type 2 diabetes with a greater risk in the presence of combined IFG and IGT. Furthermore, as will be illustrated in this review, prediabetes is associated with associated disorders typically only considered in with established diabetes. These include cardiovascular disease, periodontal disease, cognitive dysfunction, microvascular disease, blood pressure abnormalities, obstructive sleep apnea, low testosterone, metabolic syndrome, various biomarkers, fatty liver disease, and cancer. As the vast majority of individuals with prediabetes are unaware of their diagnosis, it is therefore vital that the associated conditions are identified, particularly in the presence of mild hyperglycemia, so they may benefit from early intervention.
Literatur
1.
M. Buysschaert, M. Bergman, Definition of prediabetes. Med. Clin. N. Am. 95(2), 289–297 (2011)PubMed
2.
K. Færch, K. Borch-Johnsen, J.J. Holst, A. Vaag, Pathophysiology and aetiology of impaired fasting glycemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes? Diabetologia 52, 1714–1723 (2009)PubMed
3.
R.A. DeFronzo, M.A. Ghani, Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am. J. Cardiol. 108(Suppl), 3B–24B (2011)PubMed
4.
M. Buysschaert, M. Bergman, Diagnosis of prediabetes and diabetes prevention, in Prevention of Diabetes, 1st edn., ed. by P. Schwarz, P. Reddy (Wiley, New York, 2013)
5.
M. Buysschaert, V. Preumont, J.L. Medina, M. Bergman, Global Health Perspectives in Prediabetes and Diabetes (World Scientific Publishing, Hackensack, 2014)
6.
H. Gerstein, P. Santaguida, P. Raina, K. Morrison, C. Balion, D. Hunt, H. Yazdi et al., Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic review and meta-analysis of prospective studies. Diabetes Res. Clin. Pract. 78, 305–312 (2007)PubMed
7.
A.G. Tabák, C. Herder, W. Rathmann, E.J. Brunner, M. Kivimäki, Prediabetes: a high-risk state for diabetes development. Lancet 379, 2279–2290 (2012)PubMedCentralPubMed
8.
9.
S.M. Grundy, Pre-diabetes, metabolic syndrome and cardiovascular risk. JACC 59, 635–643 (2012)PubMed
10.
J.L. Chiasson, S. Bernard, Reducing cardiovascular risk factors in patients with prediabetes. Diabetes Manag. 1(4), 423–438 (2011)
11.
L.G. Mellbin, M. Anselmino, R. Lars, Diabetes, prediabetes and cardiovascular risk. Eur. J. Cardiovasc. Prev. Rehabil. 17, S9–S14 (2010)PubMed
12.
A. Norhammar, A. Tenerz, G. Nilsson, A. Hamsten, S. Effendic, L. Ryden, G. Malmber, Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 359, 2140–2144 (2002)PubMed
13.
S. Fonville, A.A.M. Zandbergen, S.E. Vermeer, D.W.J. Dippel, P.J. Koudstaal, H.M. den Hertog, Prevalence of prediabetes and newly diagnosed diabetes in patients with a transient ischemic attack or stroke. Cerebrovasc. Dis. 36, 283–289 (2013)PubMed
14.
W.L. Lee, A.M. Cheung, D. Cape, B. Zinman, Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies. Diabetes Care 23(7), 962–968 (2000)PubMed
15.
R. Huxley, F. Barzi, M. Woodward, Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 332(7533), 73–78 (2006)PubMedCentralPubMed
16.
Emerging Risk Factors Collaboration, N. Sarwar, P. Gao, S.R. Seshasai, R. Gobin, S. Kaptoge, E. Di Angelantonio et al., Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375, 2215–2222 (2010)
17.
E.J. Brunner, M.J. Shipley, D.R. Witte, J.H. Fuller, M.G. Marmot, Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study. Diabetes Care 29(1), 26–31 (2006)PubMed
18.
B. Balkau, M. Shipley, R.J. Jarrett, K. Pyörälä, M. Pyörälä, A. Forhan, E. Eschwège, High blood glucose concentration is a risk factor mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study. The Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 21(3), 360–367 (1998)PubMed
19.
M. Coutinho, H.C. Gerstein, Y. Wang, S. Yusuf, The relationship between glucose and incident cardiovascular events. Diabetes Care 22, 233–240 (1999)PubMed
20.
E.L. Barr, P.Z. Zimmet, T.A. Welborn, D. Jolley, D.J. Magliano, D.W. Dunstan et al., Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity and lifestyle Study (AusDiab). Circulation 116(2), 151–157 (2007)PubMed
21.
B. Hoogwerf, D. Spreche, G. Pearce, M. Alevedo, J.P. Frolkis, J.M. Foody et al., Blood glucose concentration ≤125 mg/dl and coronary heart disease risk. Am. J. Cardiol. 89, 556–559 (2002)
22.
E.S. Ford, G. Zhao, C. Li, Pre-diabetes and the risk for cardiovascular disease. A systematic review of the evidence. J. Am. Coll. Cardiol. 55, 1310–1317 (2010)PubMed
23.
E.L.M. Barr, E.J. Boyko, P.Z. Zimmet, R. Wolfe, A.M. Tonkin, J.E. Shaw, Continuous relationship between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and lifestyle (AusDiab) study. Diabetologia 52, 415–424 (2009)PubMed
24.
E. Selvin, M.W. Steffes, H. Zhu, K. Matsushita, L. Wagenknecht, J. Pankow et al., Glycated hemoglobin, diabetes and cardiovascular risk in non diabetic adults. N. Engl. J. Med. 362(9), 800–811 (2010)PubMedCentralPubMed
25.
26.
A. Di Pino, R. Scicali, S. Calanna, F. Urbano, C. Mantegna, A.M. Rabuazzo et al., Cardiovascular risk profile in subjects with prediabetes and new-onset type 2 diabetes identified by HbA1c according to American Diabetes Association criteria. Diabetes Care 37, 1447–1453 (2014)PubMed
27.
J. Yeboah, A.G. Bertoni, D.M. Herrington, W.S. Post, G.L. Burke, Impaired fasting glucose and the risk of incident diabetes mellitus and cardiovascular events in an adult population. J. Am. Coll. Cardiol. 58, 140–146 (2001)
28.
B. Kowall, W. Rathmann, M. Heier, G. Giani, A. Peters, B. Thorand et al., Categories of glucose tolerance and continuous glycemic measures and mortality. Eur. J. Epidemiol. 26(8), 637–645 (2011)PubMed
29.
P. Deedwania, K. Patel, G.C. Fonarow, R.V. Desai, Y. Zhang, M.A. Feller et al., Prediabetes is not an independent risk factor for incident heart failure, other cardiovascular events or mortality in older adults: findings from a population-based cohort study. Int. J. Cardiol. 168(4), 3616–3622 (2013)PubMedCentralPubMed
30.
K. Shaye, T. Amir, S. Shlomo, S. Yechezkel, Fasting glucose levels within the high normal range predict cardiovascular outcome. Am. Heart J. 164, 111–116 (2012)PubMed
31.
For the DECODE Study Group, F. Ning, J. Tuomilehto, K. Pyörälä, A. Onat, S. Söderberg, Q. Qiao, Cardiovascular disease mortality in Europeans in relation to fasting and 2-h plasma glucose levels within a normoglycemic range. Diabetes Care 33, 2211–2216 (2010)PubMedCentral
32.
K.T. Khaw, N. Wareham, R. Luben, S. Bingham, S. Oakes, A. Welch, N. Day, Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 322, 1–6 (2001)
33.
K.T. Khaw, N. Wareham, S. Bingham, R. Luben, A. Welch, N. Day, Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann. Intern. Med. 141(6), 413–420 (2004)PubMed
34.
H.C. Gerstein, S. Islam, S. Anand, W. Almahmeed, A. Damasceno, A. Dans et al., Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15,780 patients from the INTERHEART study. Diabetologia 53, 2509–2517 (2010)PubMed
35.
Q. Qiao, K. Pyörälä, M. Pyörälä, A. Nissinen, J. Lindström, R. Tilvis, J. Tuomilehto, Two-hour glucose is better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur. Heart J. 23(16), 1267–1275 (2002)PubMed
36.
The DECODE Study Group, On behalf of the European Diabetes Epidemiology Group, Glucose tolerance and cardiovascular mortality. Comparison of fasting and 2-hour diagnostic criteria. Arch. Intern. Med. 161, 397–404 (2001)
37.
S.B. Meigs, D.M. Nathan, R.B. D’Agostino Sr, The Framingham Offspring Study. Fasting and postchallenge glycemic and cardiovascular disease risk. Diabetes Care. 25, 1845–1850 (2002)PubMed
38.
F. De Vegt, J.M. Dekker, H.G. Ruhé, C.D. Stehouwer, G. Nijpels, L.M. Bouter, R.J. Heine, Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 42(8), 926–931 (1999)PubMed
39.
M. Tominaga, H. Eguchi, H. Manaka, K. Igarashi, T. Kato, A. Sekikawa, Impaired glucose tolerance is a risk factor for cardiovascular disease but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 22(6), 920–924 (1999)PubMed
40.
K. Kato, T. Otsuka, N. Kobayashi, Y. Kon, T. Kawada, Two-hour post-load plasma glucose levels are associated with carotid intima-media thickness in subjects with normal glucose tolerance. Diabet. Med. 31(1), 76–83 (2014)PubMed
41.
Emerging Risk Factors Collaboration, S.R. Seshasai, S. Kaptoge, A. Thompson, E. Di Angelantonio, P. Gao, N. Sarwar et al., Diabetes mellitus, fasting glucose, and risk of cause-specific death. N. Engl. J. Med. 364(9), 829–841 (2011)
42.
J.A. Laukkanen, T.H. Makikallio, K. Ronkainen, J. Karppi, S. Kurl, Impaired fasting plasma glucose and type 2 diabetes are related to the risk of out-of-hospital sudden cardiac death and all-cause mortality. Diabetes Care 36, 1166–1171 (2012). doi:10.​2337/​dc12-0110 PubMed
43.
Y.S. Levitzky, M.J. Pencina, R.B. D’Agostino, J.B. Meigs, J.M. Murabito, R.S. Vasan, C.S. Fox, Impact of impaired fasting glucose on cardiovascular disease. JACC 51, 264–270 (2008)PubMed
44.
E. Selvin, J. Coresh, S.H. Golden, F.L. Brancati, A.R. Folsom, M.W. Steffes, Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch. Intern. Med. 165(16), 1910–1916 (2005)PubMed
45.
N. Sarwar, T. Aspelund, G. Eiriksdottir, R. Gobin, S.R. Seshasai, N.G. Forouhi et al., Markers of dysglycaemia and risk of coronary heart disease in people without diabetes: Reykjavik prospective study and systematic review. PLoS Med. 7(5), e1000278 (2010). doi:10.​1371/​journal.​pmed.​1000278 PubMedCentralPubMed
46.
M.V. Skriver, K. Borch-Johnsen, T. Lauritzen, HbA1c as predictor of all-cause mortality in individuals at high risk of diabetes with normal glucose tolerance, identified by screening: a follow-up study of the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION), Denmark. Diabetologia 53(11), 2328–2333 (2010)PubMed
47.
K. Faerch, D. Vistisen, N. Johansen Borup, M.E. Jorgensen, Cardiovascular risk stratifications and management in prediabetes. Curr. Diab. Rep. 14, 493 (2014)PubMed
48.
S. Kodama, K. Saito, S. Tanaka et al., Fasting and post-challenge glucose as quantitative cardiovascular risk factors: a meta-analysis. J. Atheroscler. Thromb. 19, 385–396 (2012)PubMed
49.
A.S. Gami, B.J. Witt, D.E. Howard et al., Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J. Am. Coll. Cardiol. 49, 403–414 (2007)PubMed
50.
S. Mottillo, K.B. Filion, J. Genest et al., The metabolic syndrome and cardiovascular risk : a systematic review and meta-analysis. J. Am. Coll. Cardiol. 56, 1113–1132 (2010)PubMed
51.
Y. Zhang, E.T. Lee, R.B. Devereux, J. Yeh, L.G. Best, R.R. Fabsitz, B.V. Howard, Prehypertension diabetes and cardiovascular disease risk in a population-based sample: the Strong Heart Study. Hypertension 47, 410–414 (2006)PubMed
52.
S. Milman, J.P. Crandall, Mechanisms of vascular complications in prediabetes. Med. Clin. N. Am. 95, 309–325 (2011)PubMed
53.
J. Tuomilehto, J. Lindström, J.G. Eriksson, T.T. Valle, H. Hämäläinen, P. Ilanne-Parikka et al., Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344(18), 1343–1350 (2001)PubMed
54.
R. Ratner, R. Goldberg, S. Haffner, S. Marcovina, T. Orchard, S. Fowler, Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 28(4), 888–894 (2005)PubMed
55.
W.C. Knowler, E. Barrett-Connor, S.E. Fowler, R.F. Hammam, J.M. Lachin, E.A. Walker et al., Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346(6), 393–403 (2002)PubMed
56.
T. Orchard, M. Temprosa, E. Barrett-Connor et al., Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. Diabet. Med. 30, 46–55 (2013)PubMedCentralPubMed
57.
F.B. Hu, M.J. Stampfer, S.M. Haffner, C.G. Solomon, W.C. Willett, J.E. Manson, Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 25(7), 1129–1134 (2002)PubMed
58.
J.L. Chiasson, R.G. Josse, R. Gomis, M. Hanefeld, A. Karasik, M. Laakso, Acarbose treatment and risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM trial. JAMA. 290, 486–494 (2003)PubMed
59.
E. Lonn, H. Gerstein, P. Sheridan, For the DREAM and STARR Investigations et al., Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (Study of Atherosclerosis with Ramipril and Rosiglitazone). J. Am. Coll. Cardiol. 53, 2028–2035 (2009)PubMed
60.
E.M. Lonn, J. Bosch, R. Diaz, P. Lopez-Jaramillo, A. Ramachandran, N. Hâncu et al., Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events : the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE). Diabetes Care 36(9), 2466–2474 (2013)PubMedCentralPubMed
61.
I. Hopper, B. Billah, M. Skiba, H. Krum, Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials. Eur. J. Cardiovasc. Prev. Rehabil. 18(6), 813–823 (2011)PubMed
62.
G. Li, P. Zhang, J. Wang, Y. An, Q. Gong, E.W. Gregg et al., Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet 28, 88–136 (2014). doi:10.​1016/​s2213-8587(14)70057-9
63.
M. Bergman, M. Buysschaert, P.E.H. Schwarz, A. Albright, V. Narayan, D. Yach, Diabetes prevention: global health policy and perspectives from the ground. Diabetes Manag. 2(4), 309–321 (2012)
64.
L. Rydén et al., Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD): ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with EASD. Eur. Heart J. 34, 3035–3087 (2013)PubMed
65.
American Diabetes Association, Standards of medical care in diabetes—2014. Diabetes Care 37(Suppl. 1), s14 (2014)
66.
P.M. Kearney, L. Blackwell, R. Collins, A. Keech, J. Simes, R. Peto et al., Efficacy of cholesterol-lowering therapy in 18.686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371, 117–125 (2008)PubMed
67.
P.M. Ridker, E. Danielson, F.A. Fonseca et al., JUPITER Study Group: rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195–2207 (2008)PubMed
68.
P.M. Preshaw, A.L. Alba, D. Herrera, S. Jepsen, A. Konstantinidis, K. Makrilakis, R. Taylor, Periodontitis and diabetes: a two-way relationship. Diabetelogia 55, 21–31 (2012)
69.
F. Javed, A.S.T. Alghamdi, T. Mikami, A. Mehmood, H.B. Ahemed, L.P. Samaranayake, H.C. Tenenbaum, Effect of glycemic control on self-perceived oral health, periodontal parameters, and alveolar bone loss among patients with prediabetes. J. Periodontol. 85, 234–241 (2014)PubMed
70.
N. Arora, P.N. Papapanou, M. Rosenbaum, D.R. Jacobs Jr, M. Desvarieux, R.T. Demmer, Periodontal infection, impaired fasting glucose and impaired glucose tolerance: results from The Continuous National Health and Nutrition Examination Survey 2009–2010. J. Clin. Periodontol. 41, 643–652 (2014)PubMed
71.
C.C.P. Andersen, A. Flyvbjerg, K. Buschard, P. Holmstrup, Periodontitis is associated with aggravation of prediabetes in Zucker fatty rats. J. Periodontol. 71, 1625–1631 (2007)
72.
M. Manouchehr-Pour, P.J. Spagnuolo, H.M. Rodman, N.F. Bissada, Comparison of neutrophil chemotactic response in diabetic patients with mild and severe periodontal disease. J. Periodontol. 52, 410–415 (1981)PubMed
73.
M. Altamash, S. Arledal, B. Klinge, P.-E. Engström, Pre-diabetes and diabetes: medical risk factors and periodontal conditions. Acta Odontol. Scand. 71, 1625–1631 (2013)PubMed
74.
R. McCrimmon, C.M. Ryan, M. Frier, Diabetes and cognitive dysfunction. Lancet 379, 2291–2299 (2012)PubMed
75.
T. Cukierman-Yaffe, Diabetes, dysglycemia & cognitive dysfunction. Diabetes Metab. Res. Rev. 30(5), 341–345 (2014)PubMed
76.
D.D. Schwartz, M.E. Axelrad, B.J. Andersen, Neurocognitive function in children and adolescents at the time of type 1 diabetes diagnosis: associations with glycemic control 1 year after diagnosis. Diabetes Care 37(9), 2475–2482 (2014)PubMed
77.
C. Dufouil, C. Brayne, The continuing challenge of turning promising observational evidence about risk for dementia to evidence supporting prevention. JAMA Intern. Med. 174, 333–335 (2014)PubMed
78.
79.
J.S. Roriz-Filho, T.M. Sá-Roriz, I. Rosset, A.L. Camozzato, A.C. Santos, M.L.F. Chaves, J.C. Moriguti, M. Roriz-Cruz, (Pre)diabetes, brain aging, and cognition. Biochim. Biophys. Acta 1792, 432–443 (2009)
80.
R.H. Tuligenga, A. Dugravot, A.G. Tabák, A. Elbaz, E.J. Brunner, M. Kivimäki, A. Singh-Manoux, Midlife type 2 diabetes and poor glycaemic control as risk factors for cognitive decline in early old age: a post hoc analysis of the Whitehall II cohort study. Lancet (2013). doi:10.​1016/​S2213-8587(13)70192-X PubMed
81.
G.J. Biessels, Intensive glucose lowering and cognition in type 2 diabetes. Lancet Neurol. 10, 949–950 (2011)PubMed
82.
L. Kerti, A.V. Witte, A. Winkler, U. Grittner, D. Rujescu, A. Flöel, Higher glucose levels associated with lower memory and reduced hippocampal microstructure. Neurology 81, 1746–1753 (2013)PubMed
83.
C. Anderson et al., Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET/TRANSCEND Research Programme. Diabetes Res. Clin. Pract. 83(3), 387–393 (2009)PubMed
84.
C.M. Sanz, J.-B. Ruidavets, V. Bongard, J.-C. Marquié, H. Hanaire, J. Ferrières, S. Andrieu, Relationship between markers of insulin resistance, markers of adiposity, HbA1c, and cognitive functions in a middle-aged population-based sample: the MONA LISA Study. Diabetes Care 36(6), 1512–1521 (2013)PubMedCentralPubMed
85.
Z.S. Tan, A.S. Beiser, C.S. Fox et al., Association of metabolic dysregulation with volumetric brain magnetic resonance imaging and cognitive markers of subclinical brain aging in middle-aged adults: the Framingham Offspring Study. Diabetes Care 34, 1766–1770 (2011)PubMedCentralPubMed
86.
M. Nazaribadie, K. Asgari, M. Amini, M. Ahmadpanah, M. Nazarbadie, S. Jamlipaghale, Cognitive processes and functions in patients with type 2 diabetes in comparison to pre-diabetic patients. JRHS 13(2), 208–213 (2013)PubMed
87.
T. Ohara, Y. Doi, T. Ninomiya et al., Glucose tolerance status and risk off dementia in the community: the Hisayama Study. Neurology 77, 1126–1134 (2011)PubMed
88.
P.K. Crane, R. Walker, R.A. Hubbard, G. Li, D.M. Nathan, H. Zheng, S. Haneuse, S. Craft, T.J. Montine, S.E. Kahn, W. McCormick, S.M. McCurry, J.D. Bowen, E.B. Larson, Glucose levels and risk of dementia. N. Engl. J. Med. 369, 540–548 (2013)PubMedCentralPubMed
89.
P.G. Lee, C.T. Cigolle, J. Ha, L. Min, S.L. Murphy, C.S. Blaum, W.H. Herman, Physical function limitations among middle-aged and older adults with prediabetes. Diabetes Care 36(10), 3076–3083 (2013)PubMedCentralPubMed
90.
A.L. Christman, K. Matsushita, R.F. Gottesman, T. Mosley, A. Alonso, J. Coresh, F. Hill-Briggs, A.R. Sharrett, E. Selvin, Glycated haemoglobin and cognitive decline: the Atherosclerosis Risk in Communities (ARIC) study. Diabetologia 54, 1645–1652 (2011)PubMedCentralPubMed
91.
A.M. Jacobson, Diabetes and cognitive performance: a story that is still unfolding. Diabetologia 54, 1593–1595 (2011)PubMed
92.
S.G.C. van Elderen, A. deRoos, A.J.M. de Craen et al., Progression of brain atrophy and cognitive decline in diabetes mellitus: a 3-year follow-up. Neurology 75, 997–1002 (2010)PubMed
93.
94.
G.J. Biessels, S. Staekenborg, E. Brunner, C. Brayne, P. Scheltens, Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 5, 64–74 (2006)PubMed
95.
R.N. Bryan, M. Bilello, C. Davatzikos, R.M. Lazar, A. Murray, K. Horowitz, J. Lovato, M.E. Miller, J. Williamson, L.J. Launer, Effect of diabetes on brain structure: the action to control cardiovascular risk in diabetes MR imaging baseline data. Radiology 271(1), 210–216 (2014)
96.
A. Kleinridders, H.A. Ferris, W. Cai, C.R. Kahn, Insulin action in brain regulates systemic metabolism and brain function. Diabetes 63(7), 2232–2243 (2014)PubMed
97.
A. Elbaz, M.J. Shipley, H. Nabi, E.J. Brunner, M. Kivimäki, A. Singh-Manoux, Trajectories of the Framingham general cardiovascular risk profile in midlife and poor motor function later in life: The Whitehall II study. Int. J. Cardiol. 172, 96–102 (2014). doi:10.​1016/​j.​ijcard.​2013.​12.​051 PubMedCentralPubMed
98.
L.J. Launer, M.E. Miller, J.D. Williamson, R.M. Lazar, H.C. Gertsein, A.M. Murray, M. Sullivan, K.R. Horowitz, J. Ding, S. Marcovina, L.C. Lovato, J. Lovato, K.L. Margolis, P. O’Connor, E.E. Lipkin, J. Hirsch, L. Coker, J. Maldjian, J.L. Sunshine, C. Truwit, C. Davatzikos, R.N. Bryan, For the ACCORD MIND investigators, Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND):a randomized open-label substudy. Lancet Neurol. 10, 969–977 (2011)PubMedCentralPubMed
99.
J.D. Williamson, L.J. Launer, R.N. Bryan, L.H. Coker, R.M. Lazar, H.C. Gerstein, A.M. Murray, M.D. Sullivan, K.R. Horowitz, S. Marcovina, L.C. Lovato, J. Lovato, K.L. Margolis, C. Davatzikos, J. Barzilay, H.N. Ginsberg, P.E. Linz, M.E. Miller, For the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Memory in Diabetes (MIND) investigators, Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels. JAMA Intern. Med. 174(3), 24–333 (2014)
100.
C.D. Saudek, W.H. Herman, D.B. Sacks, R.M. Bergenstal, D. Edelman, M.B. Davidson, A new look at screening and diagnosing diabetes mellitus. J. Clin. Endocrinol. Metab. 93(7), 2447–2453 (2008)PubMed
101.
S. Ghosh, A. Collier, T. Elhadd, I. Malik, Retinopathy in diabetes. Br. J. Diabetes Vasc. Dis. 10(3), 155–156 (2010)
102.
T.Y. Wong, G. Liew, R.J. Tapp, M.I. Schmidt, J.J. Wang, P. Mitchell, R. Klein, B.E. Klein, P. Zimmet, J. Shaw, Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. Lancet 371, 736–743 (2008)PubMedCentralPubMed
103.
Y.J. Cheng, E.W. Gregg, L.S. Geiss, G. Imperatore, D.E. Williams, X. Zhang, A.L. Albright, C.C. Cowie, R. Klein, J.B. Saaddine, Association of A1c and fating plasma glucose levels with diabetic retinopathy prevalence in the U.S. population. Diabetes Care 32(11), 2027–2032 (2009)PubMedCentralPubMed
104.
Diabetes Prevention Program Research Group, The prevalence of retinopathy un impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet. Med. 24, 137–144 (2007)PubMedCentral
105.
T.T. Nguyen, J.J. Wang, T.Y. Wong, Reinal vascular changes in pre-diabetes and prehypertension. Diabetes Care 30(10), 2708–2715 (2007)PubMed
106.
N. Papanas, A.I. Vinik, D. Ziegler, Neuropathy in prediabetes: does the clovk start ticking early? Nat. Rev. Endocrinol. 7, 682–690 (2011)PubMed
107.
C.J. Sumner, S. Sheth, J.W. Griffin, D.R. Cornblath, M. Polydefkis, The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 60, 108–111 (2003)PubMed
108.
B.W.C. Bongaerts, W. Rathmann, M. Heier, B. Kowall, C. Herder, D. Stöckl, C. Meisinger, D. Ziegler, Older subjects with diabetes and prediabetes are frequently unaware of having distal sensorimotor polyneuropathy. Diabetes Care 36(5), 1141–1146 (2013)PubMedCentralPubMed
109.
L.C. Plantinga, D.C. Crews, J. Coresh, E.R. Miller, R. Saran, J. Yee, E. Hedgeman, M. Pavkov, M.S. Eberhardt, D.E. Williams, N.R. Powe, For the CDC CKD Surveillance team, Prevalence of chronic kidney disease in U.S. adults with undiagnosed diabetes or prediabetes. Clin. J. Am. Soc. Nephrol. 5, 673–682 (2010)PubMedCentralPubMed
110.
H. Kramer, Screening for kidney disease in adults with diabetes and prediabetes. Curr. Opin. Nephrol. Hypertens. 14, 249–252 (2005)PubMed
111.
G.C. Curhan, Prediabetes, prehypertension…Is it time for pre-CKD? Clin. J. Am. Soc. Nephrol. 5, 557–559 (2010)PubMed
112.
O. Schnell, E. Standl, Impaired glucose tolerance, diabetes, and cardiovascular disease. Endocr. Pract. 12(1), 16–19 (2006)PubMed
113.
E.J. Diamantopoulos, E.A. Andreadis, G.I. Tsourous, P.M. Katsanou, D.X. Georgiopoulos, N.C. Nestora, S.A. Raptis, Early vascular lesions in subjects with metabolic syndrome and prediabetes. Int. Angiol. 25(2), 179–183 (2006)PubMed
114.
J.B. Meigs, M.G. Larson, R.B. D’Agostino, D. Levy, M.E. Clouse, D.M. Nathan, P.W. Wilson, C.J. O’Donnell, Coronary artery calcification in type 2 diabetes and insulin resistance: the Framingham offspring study. Diabetes Care 25(8), 1313–1319 (2002)PubMed
115.
M.W. Millar-Craig, C.N. Bishop, E.B. Raftery, Circadian variation of blood-pressure. Lancet 1(8075), 795–797 (1978)PubMed
116.
A.K. Gupta, F.L. Greenway, G. Cornelissen, W. Pan, F. Halberg, Prediabetes is associated with abnormal circadian blood pressure variability. J. Hum. Hypertens. 22(9), 627–633 (2008)PubMedCentralPubMed
117.
W.B. White, Relevance of blood pressure variation in the circadian onset of cardiovascular events. J. Hypertens. 21(6), S9–S15 (2003)
118.
R.C. Hermida, D.E. Ayala, F. Portaluppi, Circadian variation of blood pressure: the basis for the chronotherapy of hypertension. Adv. Drug Deliv. Rev. 59(9–10), 904–922 (2007)PubMed
119.
W.B. White, How well does ambulatory blood pressure predict target-organ disease and clinical outcome in patients with hypertension? Blood Press. Monit. 4(2), S17–S21 (1999)PubMed
120.
O. Torffvit, C.D. Agardh, Day and night variation in ambulatory blood pressure in type 1 diabetes mellitus with nephropathy and autonomic neuropathy. J. Intern. Med. 233(2), 131–137 (1993)PubMed
121.
F.S. Nielsen, P. Rossing, L.E. Bang, T.L. Svendsen, M.A. Gall, U.M. Smidt, H.H. Parving, On the mechanisms of blunted nocturnal decline in arterial blood pressure in NIDDM patients with diabetic nephropathy. Diabetes 44(7), 783–789 (1995)PubMed
122.
V. Spallone, M.R. Maiello, R. Morganti, S. Mandica, G. Frajese, Usefulness of ambulatory blood pressure monitoring in predicting the presence of autonomic neuropathy in type I diabetic patients. J. Hum. Hyperten. 21(7), 381–386 (2007)
123.
S. Nakano, M. Fukuda, F. Hotta, T. Ito, T. Ishii, M. Kitazawa, M. Nishizawa, T. Kigoshi, K. Uchida, Reversed circadian blood pressure rhythm is associated with occurrence of both fatal and nonfatal vascular events in NIDDM subjects. Diabetes 47(9), 1501–1506 (1998)PubMed
124.
A.K. Gupta, G. Cornelissen, F.L. Greenway, V. Dhoopati, F. Halberg, W.D. Johnson, Abnormalities in circadian blood pressure variability and endothelial function: pragmatic markers for adverse cardiometabolic profiles in asymptomatic obese adults. Cardiovasc. Diabetol. (2010). doi:10.​1186/​1475-2840-9-58 PubMedCentralPubMed
125.
B. Isak, B. Oflazoglu, T. Tanridag, I. Yitmen, O. Us, Evaluation of peripheral and autonomic neuropathy among patients with newly diagnosed impaired glucose tolerance. Diabetes Metab. Res. Rev. 24(7), 563–569 (2008)PubMed
126.
127.
Z. Putz, N. Németh, I. Istenes, T. Martos, R.A. Gandhi, A.E. Körei, Z. Hermányi, M. Szathmári, G. Jermendy, S. Tesfaye, Á.G. Tabák, P. Kempler, Autonomic dysfunction and circadian blood pressure variations in people with impaired glucose tolerance. Diabet. Med. 30(3), 358–362 (2013)PubMed
128.
J.E. Shaw, N.M. Punjabi, J.P. Wilding, K.G. Alberti, P.Z. Zimmet, Sleep-disordered breathing and type 2 diabetes: a report from the International Diabetes Federation Taskforce on Epidemiology and Prevention. Diabetes Res. Clin. Pract. 81(1), 2–12 (2008)PubMed
129.
S.R. Coughlin, L. Mawdsley, J.A. Mugarza, P.M. Calverley, J.P. Wilding, Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur. Heart J. 25(9), 735–741 (2004)PubMed
130.
N.M. Punjabi, E. Shahar, S. Redline, D.J. Gottlieb, R. Givelber, H.E. Resnick, Sleep-disordered breathing, glucose intolerance, and insulin resistance: the Sleep Heart Health Study. Am. J. Epidemiol. 160(6), 521–530 (2004)PubMed
131.
S. Seicean, H.L. Kirchner, D.J. Gottlieb, N.M. Punjabi, H. Resnick, M. Sanders, R. Budhiraja, M. Singer, S. Redline, Sleep-disordered breathing and impaired glucose metabolism in normal-weight and overweight/obese individuals: the Sleep Heart Health Study. Diabetes Care 31(5), 1001–1006 (2008)PubMed
132.
I. Muraki, T. Tanigawa, K. Yamagishi, S. Sakurai, T. Ohira, H. Imano, A. Kitamura, M. Kiyama, S. Sato, T. Shimamoto, M. Konishi, H. Iso, Nocturnal intermittent hypoxia and the development of type 2 diabetes: the Circulatory Risk in Communities Study (CIRCS). Diabetologia 53(3), 481–488 (2010)PubMed
133.
N. Botros, J. Concato, V. Mohsenin, B. Selim, K. Doctor, H.K. Yaggi, Obstructive sleep apnea as a risk factor for type 2 diabetes. Am. J. Med. 122(12), 1122–1127 (2009)PubMedCentralPubMed
134.
T. Kendzerska, A.S. Gershon, G. Hawker, G. Tomlinson, R.S. Leung, Obstructive sleep apnea and incident diabetes. A historical cohort study. Am. J. Respir. Crit. Care Med. 190(2), 218–225 (2014)PubMed
135.
136.
137.
N. Cheng, W. Cai, M. Jiang, S. Wu, Effect of hypoxia on blood glucose, hormones, and insulin receptor functions in newborn calves. Pediatr. Res. 41(6), 852–856 (1997)PubMed
138.
J.P. Chaput, J.P. Despres, C. Bouchard, A. Tremblay, Short sleep duration is associated with reduced leptin levels and increased adiposity: results from the Quebec family study. Obesity 15(1), 253–261 (2007)PubMed
139.
N. Peled, A. Greenberg, G. Pillar, O. Zinder, N. Levi, P. Lavie, Contributions of hypoxia and respiratory disturbance index to sympathetic activation and blood pressure in obstructive sleep apnea syndrome. Am. J. Hypertens. 11(11), 1284–1289 (1998)PubMed
140.
D. Einhorn, D.A. Stewart, M.K. Erman, N. Gordon, A. Philis-Tsimikas, E. Casal, Prevalence of sleep apnea in a population of adults with type 2 diabetes mellitus. Endocr. Pract. 13(4), 355–362 (2007)PubMed
141.
G.D. Foster, M.H. Sanders, R. Millman, G. Zammitt, K.E. Borradaile, A.B. Newman, T.A. Wadden, D. Kelley, R.R. Wing, F.X. Sunyer, V. Darcey, S.T. Kuna, Obstructive sleep apnea among obese patients with type 2 diabetes. Diabetes Care 32(6), 1017–1019 (2009)PubMedCentralPubMed
142.
R.S. Aronsohn, H. Whitmore, E. Van Cauter, E. Tasali, Impact of untreated obstructive sleep apnea on glucose control in type 2 diabetes. Am. J. Respir. Crit. Care Med. 181(5), 507–513 (2010)PubMedCentralPubMed
143.
R.N. Aurora, N.M. Punjabi, Obstructive sleep apnoea and type 2 diabetes mellitus: a bidirectional association. Lancet Respir. Med. 1(4), 329–338 (2013)PubMed
144.
J.M. Fredheim, J. Rollheim, T. Omland, D. Hofsø, J. Røislien, K. Vegsgaard, J. Hjelmesæth, Type 2 diabetes and pre-diabetes are associated with obstructive sleep apnea in extremely obese subjects: a cross-sectional study. Cardiovasc. Diabetol. (2011). doi:10.​1186/​1475-2840-10-84 PubMedCentralPubMed
145.
P. Levy, M.R. Bonsignore, J. Eckel, Sleep, sleep-disordered breathing and metabolic consequences. Eur. Respir. J. 34(1), 243–260 (2009)PubMed
146.
I.A. Harsch, S.P. Schahin, K. Brückner, M. Radespiel-Tröger, F.S. Fuchs, E.G. Hahn, P.C. Konturek, T. Lohmann, J.H. Ficker, The effect of continuous positive airway pressure treatment on insulin sensitivity in patients with obstructive sleep apnoea syndrome and type 2 diabetes. Respiration 71(3), 252–259 (2004)PubMed
147.
H.A. Hassaballa, A. Tulaimat, J.J. Herdegen, B. Mokhlesi, The effect of continuous positive airway pressure on glucose control in diabetic patients with severe obstructive sleep apnea. Sleep Breath. 9(4), 176–180 (2005)PubMed
148.
A.R. Babu, J. Herdegen, L. Fogelfeld, S. Shott, T. Mazzone, Type 2 diabetes, glycemic control, and continuous positive airway pressure in obstructive sleep apnea. Arch. Intern. Med. 165(4), 447–452 (2005)PubMed
149.
S.D. West, D.J. Nicoll, T.M. Wallace, D.R. Matthews, J.R. Stradling, Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes. Thorax 62(11), 969–974 (2007)PubMedCentralPubMed
150.
S. Surani, S. Subramanian, Effect of continuous positive airway pressure therapy on glucose control. World J. Diabetes 3(4), 65–70 (2012)PubMedCentralPubMed
151.
S. Pamidi, Abstract #39588. American Thoracic Society 2013 International Conference, Philadelphia, May 17–22, 2013
152.
D. Kapoor, H. Aldred, S. Clark, K.S. Channer, T.H. Jones, Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 30(4), 911–917 (2007)PubMed
153.
M. Grossmann, M.C. Thomas, S. Panagiotopoulos, K. Sharpe, R.J. Macisaac, Low testosterone levels are common and associated with insulin resistance in men with diabetes. J. Clin. Endocrinol. Metab. 93(5), 1834–1840 (2008)PubMed
154.
A.A. Al Hayek, Y.S. Khader, S. Jafal, N. Khawaja, A.A. Robert, K. Ajilouni, Prevalence of low testosterone levels in men with type 2 diabetes mellitus: a cross-sectional study. J. Fam. Community Med. 20(3), 179–186 (2013)
155.
E.L. Ding, Y. Song, V.S. Malik, S. Liu, Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 295(11), 1288–1299 (2006)PubMed
156.
157.
R. Pasquali, C. Macor, V. Vicennati, F.R. Delasio, P. Mesini, S. Boschi, F. Casimirri, R. Vettor, Effects of acute hyperinsulinemia on testosterone serum concentrations in adult obese and normal-weight men. Metabolism 46(5), 526–529 (1997)PubMed
158.
S. Bhasin, G.R. Cunningham, F.J. Hayes, A.M. Matsumoto, P.J. Snyder, R.S. Swerdloff, V.M. Montori, Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 95(6), 2536–2559 (2010)PubMed
159.
R.K. Stellato, H.A. Feldman, O. Hamdy, E.S. Horton, J.B. McKinlay, Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 23(4), 490–494 (2000)PubMed
160.
E.C. Tsai, A.M. Matsumoto, W.Y. Fujimoto, E.J. Boyko, Association of bioavailable, free, and total testosterone with insulin resistance: influence of sex hormone-binding globulin and body fat. Diabetes Care 27(4), 861–868 (2004)PubMed
161.
P. Marin, S. Homang, L. Jonsson, L. Sjostrom, H. Kvist, G. Holm, G. Lindstedt, P. Bjorntorp, The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int. J. Obes. Relat. Metab. Disord. 16(12), 991–997 (1992)PubMed
162.
S. Filippi, L. Vignozzi, A. Morelli, A.K. Chavalmane, E. Sarchielli, B. Fibbi, F. Saad, P. Sandner, P. Ruggiano, G.B. Vannelli, E. Mannucci, M. Maggi, Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. J. Sex Med. 6(12), 3274–3288 (2009)PubMed
163.
D. Goodman-Gruen, E. Barrett-Connor, Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women. Diabetes Care 23(7), 912–918 (2000)PubMed
164.
G. Corona, G. Rastrelli, G. Balercia, F. Lotti, A. Sforza, M. Monami, G. Forti, E. Mannucci, M. Maggi, Hormonal association and sexual dysfunction in patients with impaired fasting glucose: a cross-sectional and longitudinal study. J. Sex Med. 9(6), 1669–1680 (2012)PubMed
165.
C.H. Ho, H.J. Yu, C.Y. Wang, F.S. Jaw, J.T. Hsieh, W.C. Liao, Y.S. Pu, S.P. Liu, Prediabetes is associated with an increased risk of testosterone deficiency, independent of obesity and metabolic syndrome. PLoS ONE (2013). doi:10.​1371/​journal.​pone.​0074173
166.
D. Kapoor, E. Goodwin, K.S. Channer, T.H. Jones, Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur. J. Endocrinol. 154(6), 899–906 (2006)PubMed
167.
M.I. Naharci, M. Pinar, E. Bolu, A. Olgun, Effect of testosterone on insulin sensitivity in men with idiopathic hypogonadotropic hypogonadism. Endocr. Pract. 13(6), 629–635 (2007)PubMed
168.
T.H. Jones, S. Arver, H.M. Behre, J. Buvat, E. Meuleman, I. Moncada, A.M. Morales, M. Volterrani, A. Yellowlees, J.D. Howell, K.S. Channer, Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 34(4), 828–837 (2011)PubMedCentralPubMed
169.
170.
H. Beltran-Sanchez, M.O. Harhay, M.M. Harhay, S. McElligott, Prevalance and trends of metabolic syndrome in the adult U.S. population, 1999–2010. J. Am. Coll. Cardiol. 62(8), 697–703 (2013)PubMedCentralPubMed
171.
Expert Panel on Detection, Evaluation and treatment of high cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel detection, evaluation and treatment of high cholesterol in adults (Adult Treatment Panel III). JAMA 285(19), 2486–2497 (2001)
172.
S.M. Grundy, J.I. Cleeman, S.R. Daniels, K.A. Donato, R.H. Eckel, B.A. Franklin, D.J. Gordon, R.M. Krauss, P.J. Savage, S.C. Smith Jr, J.A. Spertus, F. Costa, Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol. Rev. 13(6), 322–327 (2005)PubMed
173.
K.G. Alberti, P. Zimmet, J. Shaw, The metabolic syndrome—a new worldwide definition. Lancet 366(9491), 1059–1062 (2005)PubMed
174.
G.M. Reaven, The insulin resistance syndrome: definition and dietary approaches to treatment. Annu. Rev. Nutr. 25, 391–406 (2005)PubMed
175.
R.A. DeFronzo, E. Ferrannini, Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 14(3), 173–194 (1991)PubMed
176.
C.M. Alexander, P.B. Landsman, S.M. Grundy, Metabolic syndrome and hyperglycemia: congruence and divergence. Am. J. Cardiol. 98(7), 982–985 (2006)PubMed
177.
E.J. Diamantopoulos, E.A. Andreadis, G.I. Tsourous, G.K. Ifanti, P.M. Katsanou, D.X. Georgiopoulos, C.V. Vassilopoulos, G. Dimitriadis, S.A. Raptis, Metabolic syndrome and prediabetes identify overlapping but not identical populations. Exp. Clin. Endocrinol. Diabetes 144(7), 377–383 (2006)
178.
C. Lorenzo, K. Williams, K.J. Hunt, S.M. Haffner, The National Cholesterol Education Program—Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 30(1), 8–13 (2007)PubMed
179.
C. Lorenzo, M. Okoloise, K. Williams, M.P. Stern, S.M. Haffner, The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care 26(11), 3153–3159 (2003)PubMed
180.
Q.M. Nguyen, S.R. Srinivasan, J.H. Xu, W. Chen, G.S. Berenson, Changes in risk variables of metabolic syndrome since childhood in pre-diabetic and type 2 diabetic subjects: the Bogalusa Heart Study. Diabetes Care 31(10), 2044–2049 (2008)PubMedCentralPubMed
181.
J.A. Morrison, L.A. Friedman, P. Wang, C.J. Glueck, Metabolic syndrome in childhood predicts adult metabolic syndrome and type 2 diabetes mellitus 25 to 30 years later. J. Pediatr. 152(2), 201–206 (2008)PubMed
182.
H. Florez, M.G. Temprosa, T.J. Orchard, K.J. Mather, S.M. Marcovina, E. Barrett-Connor, E. Horton, C. Saudek, X.F. Pi-Sunyer, R.E. Ratner, R.B. Goldberg, Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes Obese Metab. 16(4), 325–333 (2014)
183.
S.M. Grundy, Pre-diabetes, metabolic syndrome, and cardiovascular risk. J. Am. Coll. Cardiol. 59(7), 635–643 (2012)PubMed
184.
T.J. Orchard, M. Temprosa, R. Goldberg, S. Haffner, R. Ratner, S. Marcovina, S. Fowler, The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann. Intern. Med. 142(8), 611–619 (2005)PubMedCentralPubMed
185.
J.L. Chiasson, R.G. Josse, R. Gomis, M. Hanefeld, A. Karasik, M. Laakso, Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290(4), 486–494 (2003)PubMed
186.
R. Rajagopalan, S. Iyer, M. Khan, Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials. Curr. Med. Res. Opin. 21(1), 163–172 (2005)PubMed
187.
S. Li, H.J. Shin, E.L. Ding, R.M. van Dam, Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 302(2), 179–188 (2009)PubMed
188.
A.G. Tabak, M. Cartensen, D.R. Witte, E.J. Brunner, M.J. Shipley, M. Jokela, M. Roden, M. Kivimaki, C. Herder, Adiponectin trajectories before type 2 diabetes diagnosis. Diabetes Care 35(12), 2540–2547 (2012)PubMedCentralPubMed
189.
H. Kim, J. Jo, J.E. Lim, Y.D. Yun, S.J. Baek, T. Lee, K.B. Huh, S.H. Jee, Adiponectin as predictor for diabetes among pre-diabetic groups. Endocrine 44(2), 411–418 (2013)PubMed
190.
M.Y. Donath, D.M. Schumann, M. Faulenbach, H. Ellingsgaard, A. Perren, J.A. Ehses, Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care 31(Suppl 2), S161–S164 (2008)PubMed
191.
C.M. Larsen, M. Faulenbach, A. Vaag, A. Volund, J.A. Ehses, B. Seifert, T. Mandrup-Poulsen, M.Y. Donath, Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356(15), 1517–1526 (2007)PubMed
192.
M. Carstensen, C. Herder, M. Kivimaki, M. Jokela, M. Roden, M.J. Shipley, D.R. Witte, E.J. Brunner, A.G. Tabak, Accelereated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study. Diabetes 59(5), 1222–1227 (2010)PubMedCentralPubMed
193.
T.J. Wang, M.G. Larson, R.S. Vasan, S. Cheng, E.P. Rhee, E. McCabe, G.D. Lewis, C.S. Fox, P.F. Jacques, C. Fernandez, C.J. O’Donnell, S.A. Carr, V.K. Mootha, J.C. Florez, A. Souza, O. Melander, C.B. Clish, R.E. Gerszten, Metabolite profiles and the risk of developing diabetes. Nat. Med. 17(4), 448–453 (2011)PubMedCentralPubMed
194.
R. Wang-Sattler, Z. Yu, C. Herder, A.C. Messias, A. Floegel, Y. He, K. Heim, M. Campillos, C. Holzapfel, B. Thorand, H. Grallert, T. Xu, E. Bader, C. Huth, K. Mittelstrass, A. Doring, C. Meisinger, C. Gieger, C. Prehn, W. Roemisch-Margl, M. Carstensen, L. Xie, H. Yamanaka-Okumura, G. Xing, U. Ceglarek, J. Thiery, G. Giani, H. Lickert, X. Lin, Y. Li, H. Boeing, H. Joost, M. Hrabé de Angelis, W. Rathmann, K. Suhre, H. Prokisch, A. Peters, T. Meitinger, M. Roden, H. Wichmann, T. Pischon, J. Adamski, T. Illig, Novel biomarkers for pre-diabetes identified by metabolomics. Mol. Syst. Biol. 8, 615 (2012)PubMedCentralPubMed
195.
A. Floegel, N. Stefan, Z. Yu, K. Mühlenbruch, D. Drogan, H. Joost, A. Fritsche, H. Häring, M. Hrabe de Angelis, A. Peters, M. Roden, C. Prehn, R. Wang-Sattler, T. Illig, M.B. Schulze, J. Adamski, H. Boeing, T. Pischon, Identifcation of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomics approach. Diabetes 62(2), 639–648 (2013)PubMedCentralPubMed
196.
W.E. Gall, K. Beebe, K.A. Lawton, K. Adam, M.W. Mitchell, P.J. Nakhle, J.A. Ryals, M.V. Milburn, M. Nannipieri, S. Camastra, A. Natali, E. Ferrannini, RISC Study Group, α-Hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS ONE 5(5), e10883 (2010)PubMedCentralPubMed
197.
E. Ferranini, A. Natali, S. Camastra, M. Nannipieri, A. Mari, K. Adam, M.V. Milburn, G. Kastenmüller, J. Adamski, T. Tuomi, V. Lyssenko, L. Groop, W.E. Gall, Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance. Diabetes 62(5), 1730–1737 (2013)
198.
E. Selvin, A.M. Rawlings, M. Grams, R. Klein, A.R. Sharrett, M. Steffes, J. Coresh, Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. Lancet Diabetes Endocrinol. 2(4), 279–288 (2014)PubMed
199.
J.M. Pappachan, F.A. Antonio, M.E. Edavalath, A. Mukherjee, Non-alcoholic fatty liver disease: a diabetologist’s perspective. Endocrine 45(3), 334–353 (2014)
200.
C.P. Day, O.F. James, Steatohepatitis: a tale of two “hits”? Gastroenterology 114(4), 842–845 (1998)PubMed
201.
H. Tilg, A.R. Moschen, Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52(5), 1836–1846 (2010)PubMed
202.
M. Sargin, O. Uygur-Bayramiçli, H. Sargin, E. Orbay, A. Yayla, Association of nonalcoholic fatty liver disease with insulin resistance: is OGTT indicated in nonalcoholic fatty liver disease? J. Clin. Gastroenterol. 37(5), 399–402 (2003)PubMed
203.
V.W.S. Wong, A.Y. Hui, S.W.C. Tsang, J.L.Y. Chan, G.L.H. Wong, A.W.H. Chan, W.Y. So, A.Y.S. Cheng, P.C.Y. Tong, F.K.L. Chan, J.J.Y. Sung, H.L.Y. Chan, Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-aloholic fatty liver disease. Aliment. Pharmacol. Ther. 24(8), 1215–1222 (2006)PubMed
204.
J.W. Yun, Y.K. Cho, J.H. Park, H.J. Kim, D.I. Park, C.I. Sohn, W.K. Jeon, B.I. Kim, Abnormal glucose tolerance in young male patients with nonalcoholic fatty liver disease. Liver Int. 29(4), 525–529 (2009)PubMedCentralPubMed
205.
C. Ortiz-Lopez, R. Lomonaco, B. Orsak, J. Finch, Z. Chang, V.G. Kochunov, J. Hardies, K. Cusi, Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care 35(4), 873–878 (2012)PubMedCentralPubMed
206.
S. Zelber-Sagi, R. Lotan, O. Shibolet, M. Webb, A. Buch, D. Nitzan-Kaluski, Z. Halpern, E. Santo, R. Oren, Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up. Liver Int. 33(9), 1406–1412 (2013)PubMed
207.
B. Vozarova, N. Stefan, R.S. Lindsay, A. Saremi, R.E. Pratley, C. Bogardus, P.A. Tataranni, High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 51(6), 1889–1895 (2002)PubMed
208.
A.J. Hanley, K. Williams, A. Festa, L.E. Wagenknecht, R.B. D’Agostino Jr, J. Kempf, B. Zinman, S.M. Haffner, Insulin resistance atherosclerosis study, elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 53(10), 2623–2632 (2004)PubMed
209.
M. Nannipieri, C. Gonzales, S. Baldi, R. Posadas, K. Williams, S.M. Haffner, M.P. Stern, E. Ferrannini, Mexico City Diabetes Study, liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care 28(7), 1757–1762 (2005)PubMed
210.
Y. Doi, M. Kubo, K. Yonemoto, T. Ninomiya, M. Iwase, Y. Tanizaki, K. Shikata, M. Iida, Y. Kiyohara, Liver enzymes as predictor for incident diabetes in a Japanese population: the Hisayama study. Obesity (Silver Spring) 15(7), 1841–1850 (2007)
211.
E.S. Ford, M.B. Schulze, M.M. Bergmann, C. Thamer, H.G. Joost, H. Boeing, Liver enzymes and incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes Care 31(6), 1138–1143 (2008)PubMed
212.
A. Fraser, R. Harris, N. Sattar, S. Ebrahim, G.D. Smith, D.A. Lawlor, Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women’s Heart and Health Study and meta-analysis. Diabetes Care 32(4), 741–750 (2009)PubMedCentralPubMed
213.
G. Bedogni, S. Bellentani, L. Miglioli, F. Masutti, M. Passalacqua, A. Castiglione, C. Tiribelli, The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 6, 33 (2006)PubMedCentralPubMed
214.
B. Balkau, C. Lange, S. Vol, F. Fumeron, F. Bonnet, Group Study D.E.S.I.R., Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. BMC Gastroenterol. 10, 56 (2010)PubMedCentralPubMed
215.
I. Rückert, M. Heier, W. Rathmann, S.E. Baumeister, A. Döring, C. Meisinger, Association between markers of fatty liver disease and impaired glucose regulation in men and women from the general population: the KORA-F4-Study. PLoS ONE 6(8), e22932 (2011)PubMedCentralPubMed
216.
N. Stefan, A.M. Hennige, H. Staiger, J. Machann, F. Schick, S.M. Kröber, F. Machicao, A. Fritsche, H. Häring, α2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 29(4), 853–857 (2006)PubMed
217.
H. Ou, Y. Yang, H. Wu, J. Wu, F. Lu, C. Chang, Increased fetuin-A concentrations in impaired glucose tolerance with or without nonalcoholic fatty liver disease, but not impaired fasting glucose. J. Clin. Endocrinol. Metab. 97(12), 4717–4723 (2012)PubMed
218.
E. Giovannucci, D.M. Harlan, M.C. Archer, R.M. Bergnestal, S.M. Gapstur, L.A. Habel, M. Pollak, J.G. Regensteiner, D. Yee, Diabetes and Cancer. A consensus report. Diabetes Care 33(7), 1674–1685 (2010)PubMedCentralPubMed
219.
220.
S. Gao, A. Li, F. Liu et al., NCOA5 haploinsufficency results in glucose intolerance and subsequent heaptocellualr carcinoma. Cancer Cell 24, 725–737 (2013)PubMedCentralPubMed
221.
A. Leone, E. DiGennaro, F. Bruzzese, A. Avallone, A. Budillon, New perspective for an old antidiabteic drug: metformin as anticancer agent. Cancer Treat Res 159, 355–376 (2014)PubMed
222.
M. Bergman, R. Dankner, J. Roth, K.M. Venkat Narayan, Are current diagnostic guidelines delaying early detection of dysglycemic states? Time for new approaches. Endocrine 44(1), 66–69 (2013)PubMed
223.
M. Bergman, Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus. Endocrine 43(3), 504–513 (2013)PubMed
224.
M. Bergman, Inadequacies of current approaches to prediabetes and diabetes prevention. Endocrine 44(3), 623–633 (2013)PubMed
Metadaten
Titel
Prediabetes and associated disorders
verfasst von
Martin Buysschaert
José Luís Medina
Michael Bergman
Avni Shah
Jaqueline Lonier
Publikationsdatum
01.03.2015
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2015
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-014-0436-2

Weitere Artikel der Ausgabe 2/2015

Endocrine 2/2015 Zur Ausgabe

Original Article

Relationship between dyslipidemia and albuminuria in prediabetic adults: The Korea National Health and Nutrition Examination Survey 2011–2012

Original Article

Mouse GDF9 decreases KITL gene expression in human granulosa cells

Original Article

Activity and safety of sunitinib in patients with advanced radioactive iodine-refractory differentiated thyroid carcinoma in clinical practice

Review

PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy

Letter to the Editor

A case of nephrotic syndrome hidden by Cushing’s disease

Original Article

Relationship between autoantibodies combination, metabolic syndrome components and diabetic complications in autoimmune diabetes in adults

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise